Interim Funding: Noncompeting Renewals Reduced By 4 Percent, Competing Current Plus 7 Percent
In Brief: GAO Says Congress Should Re-Examine Delaney Clause, Consider Making It More Flexible
CALGB Grant OKed, But Group May Lose Support For Its Non-Hematologic Segments
Aging Institute Encourages Cancer Investigators To Include Elderly
BRMP Investigators Find New Lung Tumor Antigen, Seek Developers
Summit Conference Reviews Leads In Leukemia, Lymphoma
Cell Behavior Changes Noted At Baltimore Symposium
Trending Stories
- An opportunity for Trump: Position U.S. cancer science to lead the world
- Former Maryland Governor Larry Hogan to receive Public Service Leadership Award from National Coalition for Cancer Survivorship
- The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient lives
In a time of uncertainty, “react to the knowns, not the fear” - Grilled by Congress, Kennedy defends NIH and NCI budget cuts, freezes, and RIFs
To avoid “offending” pharma, NCI doesn’t study the causes of early-onset colon cancer, HHS secretary incorrectly alleges - NIH eliminates the NCI Board of Scientific Advisors
Over its 28 year history, BSA shaped NCI-funded extramural science - Kennedy’s claims notwithstanding, NCI clinical trials are delayed, enrollments reduced
NCI’s Steven A. Rosenberg: “Almost all patients are getting delayed by about a month, but then again, we’re turning away more patients.”
